A carvedilol hatásossága szívelégtelenségeben

Translated title of the contribution: The effectiveness of carvedilol in heart failure

Krisztián Kárpáti, Valentin Brodszky, Csaba Farsang, György Jermendy, Gyozo Vándorfi, Károly Zámolyi, László Gulácsi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The third generation beta-blocker (carvedilol) is effective in reduction of hypertension, and of mortality and morbidity as a supplement to conventional drugs of heart failure therapies (diuretics, ACE inhibitors), based on randomized controlled trials and retrospective analysis. Objective: To analyse the efficacy of carvedilol in the treatment of heart failure with special focused on morbidity, mortality endpoints. Methods: We assessed the multicentral, randomised, double-blind studies involving more than 150 patients (1995-2005) from MEDLINE database, in which carvedilol was used in the case of moderate to severe heart failure. We also present the results of health-economic publications (2000-2005). Results: In U.S. Carvedilol Heart Failure Study (n = 1096) the mortality declined by 65% (3.2% vs. 7.8%; p <0.001) with carvedilol vs. placebo, while the cardiovascular hospitalization decline was 27% (14.1% vs. 19.6%; p = 0.036) in heart failure (LVEF ≤35%) applied together with the basic therapy (diuretic and ACE-inhibitor). In the COPERNICUS trial the efficacy of carvedilol was compared to placebo in the case of severe HF patients (LVEF <25%, n = 2889). The annual mortality risk declined by 35% (19.7% vs. 12.8%, 95% CI: 19-48%, p = 0.00013) while the risk of mortality or any risk of hospitalisation by 24% (p = 0.00004) in the active group. The CAPRICORN study (LVEF ≤40%, n = 1959) showed that carvedilol is efficacious in reduction of total (HR: 0.77; 95% CI 0.60-0.98; p = 0.031) and cardiovascular mortality (HR: 0.75; 95% CI: 0.58-0.96; p = 0.024) as far as high-risk patients are concerned. Conclusion: The effectiveness of carvedilol is certified in reduction of mortality and hospitalization in the treatment of moderate-severe heart-failure as part of the combination therapy. The benefits of use of the drug are well measurable not only on the level of patients but on the suppliers and the financer as well, thanks to the decline of resource utilization.

Translated title of the contributionThe effectiveness of carvedilol in heart failure
Original languageHungarian
Pages (from-to)1931-1937
Number of pages7
JournalOrvosi hetilap
Volume147
Issue number40
Publication statusPublished - Oct 8 2006

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The effectiveness of carvedilol in heart failure'. Together they form a unique fingerprint.

  • Cite this

    Kárpáti, K., Brodszky, V., Farsang, C., Jermendy, G., Vándorfi, G., Zámolyi, K., & Gulácsi, L. (2006). A carvedilol hatásossága szívelégtelenségeben. Orvosi hetilap, 147(40), 1931-1937.